Regulatory and AI Round-Up: Week of 10 August 2026

Welcome to our weekly round-up for clinical operations, regulatory affairs, quality and pharmacovigilance teams. Each edition covers what moved, what it changes in your systems and SOPs, and the dates worth putting in the diary.

The short version

• FDA has scheduled its first ever advisory committee meeting on a multi-cancer early detection test, for 23 September 2026. Comments to the committee close 8 September.
• FDA proposes to reclassify digital breast tomosynthesis systems from Class III to Class II, moving a mature imaging category from premarket approval to 510(k). Comments due 9 October.
• Seven confirmed FDA action dates fall between 22 August and 30 September, heavily weighted toward rare disease, with four of them inside a single week.
• Two consecutive weeks with no AI-specific regulatory action. After a very loud start to August, that gap is worth understanding rather than ignoring.

In this round-up: MCED advisory panel · Device reclassification · AI stays quiet · The rare disease decision wave · One deal · Dates to diarise

1. FDA schedules its first advisory panel on a multi-cancer early detection test

Published 10 August 2026. Panel meets 23 September. Comments to the committee close 8 September.

FDA published a Federal Register notice convening the Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee on 23 September 2026 to discuss and vote on GRAIL's premarket approval application for the Galleri test, a next generation sequencing blood test that looks for cancer-specific methylation patterns in cell-free DNA to detect multiple cancers in adults aged 50 and over.

The notice itself is procedural. The precedent is not. This is the first time an FDA advisory panel has been convened to evaluate a multi-cancer early detection test, which makes it the reference point for every MCED and liquid biopsy programme behind it.

The evidence package is worth noting for scale. The PMA was submitted on 29 January 2026, the device has held Breakthrough Device designation since 2018, and the submission rests on the PATHFINDER 2 study with 25,490 US participants at one year of follow-up, alongside more than 70,000 participants from the NHS-Galleri trial in the UK.

What this changes operationally

If you run diagnostics or screening programmes, the panel discussion in September will be the clearest signal available on how FDA weighs large prospective screening cohorts and registry-scale follow-up in a premarket decision. That is a question about evidence architecture, not about this one product, and the answer shapes how you design the next study rather than how you finish the current one.

Two dates matter if you intend to participate. Comments must reach the committee by 8 September 2026, and the docket closes on 16 September 2026. Docket number is FDA-2026-N-8004.

Source: Federal Register, 91 FR 51496, Docket FDA-2026-N-8004, published 10 August 2026

2. FDA proposes to move digital breast tomosynthesis down to Class II

Proposed order published 10 August 2026. Comments due 9 October 2026.

FDA issued a proposed order to reclassify digital breast tomosynthesis systems, product code OTE, from Class III to Class II, creating a new classification regulation with associated special controls. In practice that means moving a widely used and well characterised imaging technology from premarket approval to 510(k) premarket notification.

The direction here is consistent and worth tracking as a pattern rather than a one-off. Where a device category is mature, well understood and supported by years of clinical use, FDA has been willing to lower the premarket burden and manage residual risk through special controls and post-market expectations instead.

What this changes operationally

For device sponsors, a reclassification of this kind changes the submission pathway and therefore the evidence plan behind it, sometimes mid-programme. If any part of your portfolio sits in a category that could plausibly follow, the useful exercise is not waiting for your own reclassification but asking whether your evidence generation is built to support either pathway.

There is also a quieter implication. Moving premarket burden downward generally moves post-market expectation upward. Special controls and continued surveillance are where the assurance goes when premarket review lightens, and that lands on quality and vigilance teams rather than regulatory affairs.

Comments are due 9 October 2026 under docket FDA-2026-N-7630.

Source: Federal Register, Docket FDA-2026-N-7630, published 10 August 2026

3. Still quiet on AI

A second consecutive week with no AI-specific regulatory action.

We checked FDA, EMA, the MHRA, ICH and the main standards and industry bodies. Nothing new and dated. The EU AI Act's general application date landed on 2 August, but the harmonised standards, Commission guidelines and delegated acts that make it operable have not started arriving, so a quiet stretch is expected rather than surprising.

4. Seven confirmed FDA action dates before the end of September

Four decisions inside one week, then a September cluster. Every date below is confirmed against the sponsor's own disclosure.

The next six weeks carry a dense run of FDA decisions, and the concentration in rare and ultra-rare disease is striking.

Dates move and decisions land early, so treat any published table as a snapshot. The lecanemab date is itself an extension from 24 May. Two dates that circulated widely for 17 August have already gone: FDA approved iberdomide on 13 August and the perioperative enfortumab vedotin and pembrolizumab regimen on 10 July.

Dates to diarise

The 15 to 17 September clash between DPHARM in Boston and RAPS Convergence in Charlotte is worth resolving early if your organisation usually sends people to both.

Back next week.

This article is for general informational purposes and does not constitute legal or regulatory advice. Regulatory positions and implementation guidance should be checked against the applicable official sources.